CARsgen Therapeutics Holdings Ltd

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies in China and the U.S. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and Phase I for pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; and CT011, which is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, which targets CD19 that is in Phase I/II clinical trial for the treatment of B cell non-Hodgkin's lymphoma; CT0180, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma; and CT0181, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in pre-clinical stage for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in pre-clinical stage for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJ-C2112, an epidermal growth factor receptor/variant III of epidermal growth factor receptor, which is in pre-clinical stage for the treatment of glioblastoma; and KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors. Further, it is developing AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company was founded in 2014 and is headquartered in Shanghai, China. Show More...